Figure 2.
Figure 2. Spectrum of EBV antigen specificity of the CTL lines. The majority of the CTLs generated from SOT patients are directed against lytic EBV antigens (Table 2). Two representative CTL lines analyzed for the presence of EBV-latent and -lytic specificities with IFN-γ ELISPOT assay and tetramers are shown. For IFN-γ ELISPOT assay (left panels), CTLs (1 × 105/well) were stimulated with a panel of peptides representing described epitopes that were informative based on the patients' HLA type. Results are shown as the mean of triplicate wells ± SD. Right panels show the same CTL lines tested using EBV-specific tetramers available for these patients based on their HLA type. Peptides are described in “Patients, materials, and methods,” under “Peptides and tetramer staining.” irr indicates irrelevant peptide.

Spectrum of EBV antigen specificity of the CTL lines. The majority of the CTLs generated from SOT patients are directed against lytic EBV antigens (Table 2). Two representative CTL lines analyzed for the presence of EBV-latent and -lytic specificities with IFN-γ ELISPOT assay and tetramers are shown. For IFN-γ ELISPOT assay (left panels), CTLs (1 × 105/well) were stimulated with a panel of peptides representing described epitopes that were informative based on the patients' HLA type. Results are shown as the mean of triplicate wells ± SD. Right panels show the same CTL lines tested using EBV-specific tetramers available for these patients based on their HLA type. Peptides are described in “Patients, materials, and methods,” under “Peptides and tetramer staining.” irr indicates irrelevant peptide.

Close Modal

or Create an Account

Close Modal
Close Modal